Navigation Links
ProFibrix Initiates Phase II Clinical Trial of its Lead Topical Hemostat Product Fibrocaps(TM)
Date:6/17/2009

SEATTLE, Washington, and LEIDEN, The Netherlands, June 18 /PRNewswire/ -- ProFibrix B.V. today announced the start of the company's Phase II clinical trial for Fibrocaps(TM), the company's lead topical Hemostat product, with the successful treatment of the first patients for mild to moderate bleeding during liver surgery. ProFibrix expects to complete the study before the end of 2009.

Fibrocaps is based on a mixture of two essential blood clotting proteins, fibrinogen and thrombin, and is a unique dry powder topical tissue sealant that rapidly stops bleeding after or during surgery. Fibrocaps has major advantages over existing liquid tissue sealants: it is ready for immediate use, is stable at room temperature, highly effective and fast acting.

ProFibrix expects to submit an Investigational New Drug Application (IND) for Fibrocaps to the U.S. Food and Drug Administration in the first half of 2010, and conduct a combined phase II/III pivotal study in various surgical indications.

Jaap Koopman, PhD, Chief Executive Officer, said: "The successful treatment of the first patients with our lead product Fibrocaps is an important milestone for the company. With focus and dedication we have made enormous progress over the past two years, and we are on track to bring Fibrocaps to the point of market approval."

About ProFibrix

ProFibrix was founded in 2004 and is headquartered in Leiden, The Netherlands, with a subsidiary in Seattle, WA. The company leverages its expertise in fibrinogen technology to develop and market innovative products for the hemostasis and regenerative medicine markets. Human fibrinogen plays a pivotal role in blood clotting and tissue healing. ProFibrix is led by a team with extensive commercial, clinical and scientific experience in the hemostasis field.


'/>"/>
SOURCE ProFibrix B.V.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. ProFibrix Steps up Recombinant Fibrinogen Program With PER.C6(R) License From Crucell
2. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
3. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
4. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
5. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
6. VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
7. Osprey Pharmaceuticals U.S.A., Inc. Initiates Phase Ib Clinical Trial in IgA Nephropathy
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
10. Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
11. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , April 29, 2016 ... Review, H1 2016" market research report that provides ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ... It also reviews key players involved in the ...
(Date:4/29/2016)... , April 29, 2016 ... for Life Sciences, Product Development Capabilities in ... Science Customer Base . Indegene ... today announced the acquisition of Skura Corporation,s life ... leader in adaptive sales enablement technology for life ...
(Date:4/29/2016)... 2016 Interview ... Sanofi, leader mondial et diversifié ... pour le premier trimestre 2016. Le ... commente les résultats du premier trimestre ... le reste de l,année. ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... , ... Spine Team Texas, a comprehensive spine physician group specializing in the ... has been invited to be a featured speaker at the Texas Society of the ... 30, 2016. , Dr. R. Scott McPherson, a physical medicine and rehabilitation specialist, ...
(Date:4/29/2016)... ... April 29, 2016 , ... Mobility Designed is redefining mobility with their ... the M+D Crutch evenly distributes body weight from the elbow to the forearm. ... the crutches than with other crutches. , Co-founders Max and Liliana Younger were inspired ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... Celiac Association (CCA), is pleased to announce the launch of the GFCP ... articles, recipes, and more. The purpose of the GFCP Scoop site ...
(Date:4/29/2016)... ... 29, 2016 , ... Dr. Robert Mondavi, one of the dentists in ... is a fast-growing field as more patients are discovering the many different ways they ... the options currently available to them and which ones might work for their smiles. ...
(Date:4/29/2016)... Hills, CA (PRWEB) , ... April 29, 2016 , ... ... of devices and products for the head and neck/ear, nose and throat specialty, has ... Device , The KOTLER NASAL AIRWAY™ is a newly patented safety device ...
Breaking Medicine News(10 mins):